Weizhe Huang1,2,3,4, Shen Zhao5, Wei Xu6, Zhikui Zhang6, Xiangdong Ding6, Jianxing He2,3,4, Wenhua Liang2,3,4. 1. Department of Thoracic Surgery, the First Affiliated Hospital, Medical College of Shantou University, Shantou 515041, China. 2. Department of Thoracic Surgery/Oncology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China. 3. Guangzhou Institute of Respiratory Disease & Health, Guangzhou 510120, China. 4. China State Key Laboratory and National Clinical Research Center for Respiratory Disease, Guangzhou 510120, China. 5. Department of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China. 6. Guangzhou KingMed Center for Clinical Laboratory Co. Ltd., Guangzhou 510000, China.
Abstract
BACKGROUND: Lung is a reservoir for megakaryocytes (MKs). The relationship between intra-tumoral MKs and non-small cell lung cancer (NSCLC) is unknown. We investigate relationship between high intra-tumoral MKs with the recurrence of NSCLC. METHODS: The tissue sections of 629 patients with resected NSCLC were stained with hematoxylin, anti-CD61, anti-CD34 and stromal cell-derived factor-1 (SDF-1). CD61+ giant cells localized in CD34+ capillaries were identified as MKs. The impact of MKs and preoperative platelet count on disease-free survival (DFS) was investigated. RESULTS: Overall, 18.9% of patients were positive for the presence of MKs. In univariate analysis, the median DFS of the MK+ group was shorter than the median DFS of the MK- group (69.1 vs. 80.5 months; P=0.021). Multivariate analysis indicated that MKs in tumor tissue was an unfavorable prognostic factor for DFS (HR 1.351, P=0.065), the impact of which was more significant in non-squamous cell carcinoma (NSCC) (HR 1.710, P=0.008) and in patients with N0 (HR 1.883, P=0.009). Although systemic platelet count of the MK+ group was significantly higher than the MK- group (270.6×109 vs. 243.6×109/L, P=0.007), the stratified subgroup DFS curves (P=0.003) showed that the effect of MKs on prognosis was independent of the blood platelet count. CONCLUSIONS: Our results demonstrate that CD61+ MKs in tumor tissue predict unfavorable prognosis in NSCLC.
BACKGROUND: Lung is a reservoir for megakaryocytes (MKs). The relationship between intra-tumoral MKs and non-small cell lung cancer (NSCLC) is unknown. We investigate relationship between high intra-tumoral MKs with the recurrence of NSCLC. METHODS: The tissue sections of 629 patients with resected NSCLC were stained with hematoxylin, anti-CD61, anti-CD34 and stromal cell-derived factor-1 (SDF-1). CD61+ giant cells localized in CD34+ capillaries were identified as MKs. The impact of MKs and preoperative platelet count on disease-free survival (DFS) was investigated. RESULTS: Overall, 18.9% of patients were positive for the presence of MKs. In univariate analysis, the median DFS of the MK+ group was shorter than the median DFS of the MK- group (69.1 vs. 80.5 months; P=0.021). Multivariate analysis indicated that MKs in tumor tissue was an unfavorable prognostic factor for DFS (HR 1.351, P=0.065), the impact of which was more significant in non-squamous cell carcinoma (NSCC) (HR 1.710, P=0.008) and in patients with N0 (HR 1.883, P=0.009). Although systemic platelet count of the MK+ group was significantly higher than the MK- group (270.6×109 vs. 243.6×109/L, P=0.007), the stratified subgroup DFS curves (P=0.003) showed that the effect of MKs on prognosis was independent of the blood platelet count. CONCLUSIONS: Our results demonstrate that CD61+ MKs in tumor tissue predict unfavorable prognosis in NSCLC.
Authors: Hansjörg Schwertz; Sarah Köster; Walter H A Kahr; Noemi Michetti; Bjoern F Kraemer; David A Weitz; Robert C Blaylock; Larry W Kraiss; Andreas Greinacher; Guy A Zimmerman; Andrew S Weyrich Journal: Blood Date: 2010-01-19 Impact factor: 22.113
Authors: Rajkumar Savai; Joachim C Wolf; Susanne Greschus; Bastian G Eul; Ralph T Schermuly; Jörg Hänze; Robert Voswinckel; Alexander C Langheinrich; Friedrich Grimminger; Horst Traupe; Werner Seeger; Frank Rose Journal: Am J Pathol Date: 2005-10 Impact factor: 4.307
Authors: Irem H Ozbudak; Konstantin Shilo; Sabine Hale; Nadine S Aguilera; Jeffrey R Galvin; Teri J Franks Journal: Arch Pathol Lab Med Date: 2008-01 Impact factor: 5.534
Authors: Sachin Narayan; George Courcoubetis; Jeremy Mason; Amin Naghdloo; Drahomír Kolenčík; Scott D Patterson; Peter Kuhn; Stephanie N Shishido Journal: Cancers (Basel) Date: 2022-10-06 Impact factor: 6.575
Authors: Desiree Loreth; Moritz Schuette; Jenny Zinke; Malte Mohme; Andras Piffko; Svenja Schneegans; Julia Stadler; Melanie Janning; Sonja Loges; Simon A Joosse; Katrin Lamszus; Manfred Westphal; Volkmar Müller; Markus Glatzel; Jakob Matschke; Christoffer Gebhardt; Stefan W Schneider; Iwona Belczacka; Beate Volkmer; Rüdiger Greinert; Marie-Laure Yaspo; Patrick N Harter; Klaus Pantel; Harriet Wikman Journal: Int J Mol Sci Date: 2021-06-29 Impact factor: 5.923